Canzon Israel Ltd - Asset Resilience Ratio
Canzon Israel Ltd (CNZN) has an Asset Resilience Ratio of 0.73% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Canzon Israel Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Canzon Israel Ltd's Asset Resilience Ratio has changed over time. See CNZN total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Canzon Israel Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Canzon Israel Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA33.00K | 0.73% |
| Total Liquid Assets | ILA33.00K | 0.73% |
Asset Resilience Insights
- Limited Liquidity: Canzon Israel Ltd maintains only 0.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Canzon Israel Ltd Industry Peers by Asset Resilience Ratio
Compare Canzon Israel Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ipsen SA
PA:IPN |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 6.06% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 35.10% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915 |
Drug Manufacturers - Specialty & Generic | 25.22% |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505 |
Drug Manufacturers - Specialty & Generic | 11.06% |
Annual Asset Resilience Ratio for Canzon Israel Ltd (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Canzon Israel Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.49% | ILA26.00K ≈ $69.71 |
ILA5.25 Million ≈ $14.08K |
-0.89pp |
| 2022-12-31 | 1.39% | ILA137.00K ≈ $367.29 |
ILA9.89 Million ≈ $26.51K |
-6.99pp |
| 2021-12-31 | 8.37% | ILA1.10 Million ≈ $2.95K |
ILA13.13 Million ≈ $35.20K |
-11.61pp |
| 2016-12-31 | 19.98% | ILA1.86 Million ≈ $4.98K |
ILA9.30 Million ≈ $24.92K |
-0.15pp |
| 2015-12-31 | 20.13% | ILA1.80 Million ≈ $4.82K |
ILA8.93 Million ≈ $23.94K |
+6.55pp |
| 2014-12-31 | 13.57% | ILA1.25 Million ≈ $3.35K |
ILA9.21 Million ≈ $24.69K |
-5.33pp |
| 2013-12-31 | 18.90% | ILA2.86 Million ≈ $7.66K |
ILA15.13 Million ≈ $40.55K |
+3.93pp |
| 2012-12-31 | 14.97% | ILA3.24 Million ≈ $8.68K |
ILA21.61 Million ≈ $57.94K |
-- |
About Canzon Israel Ltd
Canzon Israel Ltd focuses on investing and managing projects in the field of initiating construction for residential and commercial purposes in Portugal. The company was formerly known as User Trend Ltd and changed its name into Canzon Israel Ltd in June 2019. Canzon Israel Ltd was incorporated in 1999 and is based in Tel Aviv, Israel.